BlackRock’s Citius Oncology CTOR Stock Holding History

BlackRock’s Portfolio CTOR Stock Details CTOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-47,454	Closed	-$29.4K	–	5916
2026 Q1	$29.4K	Buy	47,454 +25,110	+112%	+$25.2K	﹤0.01%	5239
2025 Q4	$22.3K	Buy	+22,344	New	+$32.1K	﹤0.01%	5199

Other funds holding CTOR

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock's CTOR Position: Q2 2026 in Review

BlackRock sold out of Citius Oncology (CTOR) in Q2 2026, closing a stake of 47,454 shares — an estimated $29.4K sold.

BlackRock first reported a position in CTOR in Q4 2025 and held it in 2 quarters. The position peaked at $29.4K in Q1 2026. 19 funds tracked by Wall St. Rank hold CTOR as of Q2 2026.

BlackRock reported no remaining Citius Oncology position as of Q2 2026 after selling out during the quarter.
BlackRock sold 47,454 Citius Oncology shares in Q2 2026, an estimated $29.4K.
BlackRock first reported a position in Citius Oncology in Q4 2025 and held it in 2 quarters.
BlackRock's Citius Oncology position peaked at $29.4K in Q1 2026.
19 funds tracked by Wall St. Rank held Citius Oncology as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.